Cmp¹Ú¾ü

Cmp(¹Ú¾ü)¹ÙÍø - Î÷¼×Ï£ºé¾º¼¼Ö÷ÔÞÖúÉÌ
¿ÆÆÕ¶¯Ì¬
¹Ø×¢Cmp¹Ú¾ü΢ÐŹ«ÖںŻñÈ¡¼´Ê±ÐÂÎÅ

¡¾ÏàÖú½ÒÏþ¡¿|¿¨½éÃçÓÕµ¼µÄµ¥ºËϸ°ûÑùTHP-1ϸ°ûѵÁ·ÃâÒߣ¨trained immunity£©ÌåÍâÄ£×ӵĽ¨Éè

ȪԴ£ºCmp¹Ú¾üÉúÎï Ðû²¼£º2024-05-01 ÔĶÁ£º3034

640

½üÆÚ£¬¸´µ©´óѧÁ¥ÊôÉϺ£Êй«¹²ÎÀÉúÁÙ´²ÖÐÐÄ/ÉϺ£ÊÐÖØ´óѬȾ²¡ºÍÉúÎïÇå¾²Ñо¿Ôº£¨¼ò³Æ¹«ÎÀÖÐÐÄ/Êд«ÑÐÔº£©¡¢ÉϺ£Cmp¹Ú¾üÉúÎïÊÖÒÕÓÐÏÞ¹«Ë¾/Õã½­×ÔóÇøCmp¹Ú¾üÉúÎïÒ½Ò©¿Æ¼¼ÓÐÏÞ¹«Ë¾£¨¼ò³ÆCmp¹Ú¾üÉúÎÏàÖú̽Ë÷ÁËÌâΪ¡°Establishment of an in vitro model of monocyte-like THP-1 cells for trained immunity induced by bacillus Calmette-Gu¨¦rin/¿¨½éÃçBCGÓÕµ¼µÄµ¥ºËϸ°ûÑùTHP-1ϸ°ûѵÁ·ÃâÒßÌåÍâÄ£×ӵĽ¨É衱µÄÑо¿¡£¸ÃÑо¿Ð§¹ûÒÑÓÚ2024.04.20ÈÕ½ÒÏþÓÚ¡¶BMC Microbiology¡·£¨IF = 4.2£©¡£¸ÃÑо¿Óɹ«ÎÀÖÐÐÄ/Êд«ÑÐÔºµÄÐì½ø´¨²©Ê¿ºÍCmp¹Ú¾üÉúÎïµÄÎ⿵²©Ê¿ÎªÅäºÏµÚÒ»×÷Õߣ¬¹«ÎÀÖÐÐÄ/Êд«ÑÐÔºµÄ·¶Ð¡Ó½ÌÊÚΪͨѶ×÷Õß¡£

Åä¾°

·ÖÖ¦¸Ë¾úѪÁ÷ѬȾÔÚÃâÒß¹¦Ð§µÍϵÄÈËȺÖкܳ£¼û£¬Í¨³£»á´øÀ´ÔÖÄÑÐÔµÄЧ¹û¡£×÷ΪѪÁ÷ÖеÄÖ÷ÒªÍÌÊÉϸ°û£¬µ¥ºËϸ°ûºÍÖÐÐÔÁ£Ï¸°ûÔÚ¶Ô¿¹ÑªÁ÷·ÖÖ¦¸Ë¾úѬȾÖÐÊ©Õ¹×ÅÒªº¦×÷Óá£Óë¾ÞÊÉϸ°ûÏà·´£¬µ¥ºËϸ°û¶Ô·ÖÖ¦¸Ë¾úѬȾӦ´ðµÄÑо¿½ÏÉÙ¡£
Ч¹û
ÔÚÕâÏîÑо¿ÖУ¬ÎÒÃÇÊ×ÏȽ¨ÉèÁËÒ»ÖÖ¿¨½éÃçBCGѬȾ·ÇÌù±Úµ¥ºËϸ°ûÑùTHP-1ϸ°û£¨¼´Ã»ÓÐÓɷ𲨴¼12-ÈⶹޢËáõ¥13-ÒÒËáõ¥£¨¼´PMA£©ÓÕµ¼·Ö½â£©µÄÁ÷³Ì¡£Æ¾Ö¤¸ÃÁ÷³Ì£¬ÎÒÃÇͨ¹ýRNA-seq̽Ë÷ÁËѬȾBCGµÄ·ÇÌù±ÚTHP-1ϸ°ûµÄת¼×飬·¢Ã÷NF-¦ÊB¡¢MAPKºÍPI3K-AktÐźÅͨ·ÒÔ¼°Ò»Ð©Ñ×Ö¢Ç÷»¯Òò×Ó/ϸ°ûÒò×Ó»ùÒò£¨ºÃ±ÈCCL4¡¢CXCL10¡¢TNFºÍIL-1¦Â£©µÄ±í´ï»ñµÃÔöÇ¿¡£ÁîÈ˾ªÑȵÄÊÇ£¬¼ÓÈëѵÁ·ÃâÒßµÄAkt-HIF-mTORÐźÅͨ·Ҳ±»Éϵ÷¡£ÔÚ¸ÃÌåÍâѬȾģ×ÓÖУ¬ÊӲ쵽ϸ°ûÒò×Ó¶ÔÖ¬¶àÌÇ£¨¼´LPS£©Ôٴ̼¤µÄ·´Ó¦ÔöÌí¡¢Ï¸°û»îÁ¦Ìá¸ßÒÔ¼°°×É«ÄîÖé¾ú£¨Candida albicans£©¸ººÉïÔÌ­¡£
½áÂÛ
ÎÒÃÇÊ״ν¨ÉèÁËBCG¸ßЧѬȾ·ÇÌù±ÚTHP-1ϸ°ûµÄÁ÷³Ì¡¢Ê×´Î̽Ë÷ÁËBCG ѬȾµÄ·ÇÌù±Ú THP-1 ϸ°ûµÄת¼×é¡¢²¢Ê״ν¨ÉèÁËѵÁ·ÃâÒßµÄÌåÍâϸ°ûÄ£×Ó¡£
640 (1)

Óà BCG ѬȾ·ÇÌù±Ú THP-1 ϸ°û²¢Í¨¹ýMACS´Ó°ûÍâBCGÖзÖÑ¡THP-1ϸ°ûµÄʾÒâͼ


640 (2)
ÓëѵÁ·ÃâÒßÏà¹ØµÄGSEAЧ¹û
640 (3)
¶ÌÆÚѵÁ·ÃâÒßʾÒâͼ
¸ÃÑо¿½¨ÉèµÄÏà¹ØÁ÷³Ì£¨¼´BCGѬȾÐü¸¡µÄTHP-1ϸ°û£©ºÍÄ£×Ó£¨¼´ÌåÍâѵÁ·ÃâÒߣ©£¬ÓÐÍûΪÐü¸¡Ï¸°ûºÍ²¡Ô­Ï¸¾ú/Õæ¾úµÄ»¥×÷Ñо¿¡¢Ö×ÁöÖÎÁÆ£¨ºÃ±È°òë×°©£©¡¢Ï¸°ûÒßÃçÃâÒߣ¨ºÃ±È¿¹½áºË£©Ìṩ˼Ð÷ºÍ²Î¿¼¡£
¡¾ÍøÕ¾µØͼ¡¿¡¾sitemap¡¿